太原痔疮手术很疼吗太原大便出血怎么了,太原肛肠医院医院,太原肛周脓肿会有哪些症状,山西痔疮怎么好,太原什么样是痔疮,山西治肛肠科疾病医院,太原大便完以后有血怎么回事

BEIJING, Sept. 26 (Xinhuanet) -- Young unmarried migrant women are facing a high risk of induced abortions in China and experts urged that they have better access to reproductive health education.Among the 8 to 10 million induced abortions performed on the mainland each year, nearly 47 percent involve unmarried women younger than 25, according to Cheng Linan, director of the center for clinical research and training of the Shanghai Institute of Planned Parenthood Research.The statistics are based on the results from a recent nationwide survey."The rising trend of induced abortions is even more evident among migrants who usually have poor awareness and access to reproductive health knowledge and services, particularly about contraception," she said on Saturday at an event to mark World Contraceptive Day, which falls on Sept 26.A 2008 survey involving more than 50,000 induced abortions in Beijing showed that roughly 70 percent of the women undergoing the procedure were migrants. For many, it was not their first abortion.According to a nationwide study by the Chinese Medical Association (CMA), of all women having received induced abortions, nearly 56 percent had two operations and 13.5 percent had three or more."That not only causes the women certain physical or mental problems, but it also gives the country a huge economic burden of more than 3 billion yuan" or about 0 million, she said.Among Chinese women who became infertile, more than 88 percent previously had an induced abortion, a study conducted in 2007 showed.Other potential health hazards include hemorrhage, uterine or pelvic infection, uterine perforation and cervical laceration.Apart from low awareness, poor access to professional consultations on contraception, particularly among single young women, is mainly the problem.A 2011 survey by the CMA found that about 44 percent of those polled said they had difficulty accessing scientifically correct contraceptive information, compared with a global average of 15.5 percent.

BEIJING, July 22 (Xinhuanet) -- Regulation is needed to govern rapidly expanding research in animals containing human tissue or genes, according to the Britain's Academy of Medical Sciences.Using animals with limited humanized traits is not new. Genetically engineered mice containing human DNA are already a mainstay of research into new drugs for diseases like cancer.For instance, Chinese scientists have already introduced human stem cells into goat fetuses and U.S. researchers have studied the idea of creating a mouse with human brain cells.But Martin Bobrow, a professor of medical genetics at the University of Cambridge, who led the Academy's working group, said there were three areas of particular concern."Where people begin to worry is when you get to the brain, to the germ cells, and to the sort of central features that help us recognize what is a person, like skin texture, facial shape and speech," he said.His report recommends that government should put in place a national expert body, working within the existing system for regulating animal research, to oversee such sensitive areas.British ministers said they welcomed the report and would consider its recommendations carefully.

SINGAPORE, June 14 (Xinhua) -- Researchers from Singapore and China are conducting a research aimed at using different technologies to completely capture and convert carbon dioxide in industrial emissions into energy, local daily Lianhe Zaobao reported on Tuesday.The project, supported by the National Research Foundation (NSF) of Singapore, will make use of sunlight as well as photochemical and photosynthetic processes, the foundation said.The researchers involved in the five-year project are from China's Peking University and Singapore's National University of Singapore and the Nanyang Technological University. A research center will be established under the Campus for Research Excellence and Tehnological Enterprise, a program also known as CREATE, the foundation said.It will be the first project involving cooperation with a Chinese university under the program. It will be located at the University Town of the National University of Singapore due to be completed by the end of the year.Lee Yuan-Kun, a researcher at the National University of Singapore, said no single chemical process can capture and convert the carbon dioxide completely so the researchers will be first treating the emissions with photochemical and electrochemical processes to convert most of the carbon dioxide into energy resources such as methane.The gas with thinner carbon dioxide will then be used to grow microalgae, he said.Nevertheless, for the cost of renewable energy to be close to that of fossil fuel, the efficiency will have to be drastically improved by about five to 10 times, Lee said.The project is one of three energy research projects to be housed under the Campus for Research Excellence and Tehnological Enterprise program.Zhang Dongxiao, from the College of Engineering at Peking University, said that the research program seeks to develop energy efficient and environmentally friendly carbon capture technologies that can be applied in the manufacturing and chemical industries, and that it complements Peking University's strong capability in carbon storage."Reducing carbon intensity will not only benefit both countries in terms of cost competitiveness of products made, but also portrays a good image on our national responsibility to achieve a sustainable Earth," Zhang said. 

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

BERLIN, July 26 (Xinhua) -- German national disease control center said on Tuesday that the country's deadly E. coli outbreak has been over, as no new case reported in the last three weeks.The Robert Koch Institute (RKI) said the last case related to the E.coli outbreak was reported on July 4.As a three-week-period would cover the disease's incubation time, diagnosis time and the time for the transfer of a case, this virtually means an end of the outbreak."The largest EHEC outbreak is over in Germany," said RKI President Reinhard Burger. "I pay tribute to people who have joined in the great work, making investigation and looking after the patients."The RKI said Germany would keep watching the deadly EHEC O104: H4 intensively and asked people to pay attention to personal and food hygiene, as individual infection still cannot be ruled out.This round of outbreak has claimed 52 lives and affected more than 4,000 people since early May.The source of this disease was first believed to be cucumbers and tomatoes from Spain, and then was locked onto bean sprouts grown in a farm near Hamburg in the state Lower Saxony. Later European authorities said one batch of fenugreek seeds from Egypt was probably the source.